The estimated Net Worth of Adrian Adams is at least 453 千$ dollars as of 15 June 2020. Mr. Adams owns over 100,000 units of Akebia Therapeutics stock worth over 257,400$ and over the last 19 years he sold AKBA stock worth over 0$. In addition, he makes 195,966$ as Independent Chairman of the Board at Akebia Therapeutics.
Adrian has made over 4 trades of the Akebia Therapeutics stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 100,000 units of AKBA stock worth 129,000$ on 15 June 2020.
The largest trade he's ever made was buying 500,000 units of Akebia Therapeutics stock on 15 March 2017 worth over 1,230,000$. On average, Adrian trades about 27,885 units every 99 days since 2005. As of 15 June 2020 he still owns at least 178,750 units of Akebia Therapeutics stock.
You can see the complete history of Mr. Adams stock trades at the bottom of the page.
Adrian Adams serves as Independent Chairman of the Board of the Company. Mr. Adams has served as a member of our Board of Directors since completion of the Merger in December 2018. From February 2016 to January 2019, Mr. Adams served as Chief Executive Officer of Aralez Pharmaceuticals Inc., a pharmaceutical company that focuses on the development, acquisition and commercialization of cardiovascular, pain and other therapies (now Old API Wind-Down Ltd. (Nasdaq: ARLZ)), and was a member of the Aralez Board of Directors from February 2016 to March 2019. From May 2015 to February 2016, Mr. Adams was the Chief Executive Officer and served on the Board of Directors of POZEN, Inc., a pharmaceutical company which was combined with Tribute Pharmaceuticals Canada Inc. to become Aralez Pharmaceuticals Inc. in 2016. Aralez voluntarily commenced restructuring proceedings in Canadian Court and its U.S.-based subsidiaries, including POZEN, Inc., filed voluntary petitions for relief under Chapter 11 of the U.S. Bankruptcy Code, in August 2018. Previously, Mr. Adams served as Chief Executive Officer, President and a director of Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, from December 2011 until January 2015, when it was acquired by Endo International plc. Prior to these roles, Mr. Adams served in several chief executive officer positions at leading specialty pharmaceutical companies including Kos Pharmaceuticals, Inc., Sepracor, Inc. and Inspire Pharmaceuticals, Inc. Mr. Adams served as Chief Executive Officer of Neurologix, Inc., a company which filed for bankruptcy under Chapter 7 in 2012, from September 2011 until November 2011. Mr. Adams has also held general management and senior international and national marketing positions at Novartis, SmithKline Beecham and ICI (now part of AstraZeneca). Mr. Adams also serves as the Chairman of the Board of Directors at AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX). Mr. Adams graduated from the Royal Institute of Chemistry at Salford University.
As the Independent Chairman of the Board of Akebia Therapeutics, the total compensation of Adrian Adams at Akebia Therapeutics is 195,966$. There are 9 executives at Akebia Therapeutics getting paid more, with John Butler having the highest compensation of 4,316,960$.
Adrian Adams is 69, he's been the Independent Chairman of the Board of Akebia Therapeutics since 2018. There are no older and 19 younger executives at Akebia Therapeutics.
Adrian's mailing address filed with the SEC is C/O AKEBIA THERAPEUTICS, INC., 245 FIRST ST., CAMBRIDGE, MA, 02142.
Over the last 11 years, insiders at Akebia Therapeutics have traded over 3,056,393$ worth of Akebia Therapeutics stock and bought 2,141,907 units worth 27,915,834$ . The most active insiders traders include Holdings A/S Novo、Muneer A Satter、Mark J Enyedy. On average, Akebia Therapeutics executives and independent directors trade stock every 28 days with the average trade being worth of 43,534$. The most recent stock trade was executed by Nicole R. Hadas on 13 May 2024, trading 12,016 units of AKBA stock currently worth 15,140$.
akebia therapeutics, inc. is a biopharmaceutical company headquartered in cambridge, massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (hif) biology. akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. akebia’s global phase 3 program for vadadustat, which includes the pro2tect studies for non-dialysis patients with anemia associated with chronic kidney disease and the inno2vate studies for dialysis-dependent patients, is currently ongoing. for more information, please visit our website at www.akebia.com.
Akebia Therapeutics executives and other stock owners filed with the SEC include: